These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18187807)

  • 1. Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization.
    Claes A; Wesseling P; Jeuken J; Maass C; Heerschap A; Leenders WP
    Mol Cancer Ther; 2008 Jan; 7(1):71-8. PubMed ID: 18187807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.
    Navis AC; Hamans BC; Claes A; Heerschap A; Jeuken JW; Wesseling P; Leenders WP
    J Pathol; 2011 Apr; 223(5):626-34. PubMed ID: 21341272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
    Grossman R; Tyler B; Rudek MA; Kim E; Zadnik P; Khan U; Blakeley JO; Pathak AP; Brem H
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):93-100. PubMed ID: 23649683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment.
    Claes A; Gambarota G; Hamans B; van Tellingen O; Wesseling P; Maass C; Heerschap A; Leenders W
    Int J Cancer; 2008 May; 122(9):1981-6. PubMed ID: 18081012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
    Chahal M; Xu Y; Lesniak D; Graham K; Famulski K; Christensen JG; Aghi M; Jacques A; Murray D; Sabri S; Abdulkarim B
    Neuro Oncol; 2010 Aug; 12(8):822-33. PubMed ID: 20179017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
    Folkins C; Man S; Xu P; Shaked Y; Hicklin DJ; Kerbel RS
    Cancer Res; 2007 Apr; 67(8):3560-4. PubMed ID: 17440065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin.
    Li XQ; Ouyang ZG; Zhang SH; Liu H; Shang Y; Li Y; Zhen YS
    Cancer Biol Ther; 2014 Apr; 15(4):398-408. PubMed ID: 24424202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.
    Mathieu V; De Nève N; Le Mercier M; Dewelle J; Gaussin JF; Dehoux M; Kiss R; Lefranc F
    Neoplasia; 2008 Dec; 10(12):1383-92. PubMed ID: 19048117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme.
    Baumann F; Bjeljac M; Kollias SS; Baumert BG; Brandner S; Rousson V; Yonekawa Y; Bernays RL
    J Neurooncol; 2004; 67(1-2):191-200. PubMed ID: 15072467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.
    Zhang YH; Yue ZJ; Zhang H; Tang GS; Wang Y; Liu JM
    Eur J Pharm Biopharm; 2010 Nov; 76(3):371-5. PubMed ID: 20816959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.
    Zhou Q; Guo P; Gallo JM
    Clin Cancer Res; 2008 Mar; 14(5):1540-9. PubMed ID: 18316579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
    Grossman R; Brastianos H; Blakeley JO; Mangraviti A; Lal B; Zadnik P; Hwang L; Wicks RT; Goodwin RC; Brem H; Tyler B
    J Neurooncol; 2014 Jan; 116(1):59-65. PubMed ID: 24185441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms.
    Jo MY; Kim YG; Kim Y; Lee SJ; Kim MH; Joo KM; Kim HH; Nam DH
    Mol Med Rep; 2012 Jul; 6(1):88-92. PubMed ID: 22505191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.
    Golubovskaya VM; Huang G; Ho B; Yemma M; Morrison CD; Lee J; Eliceiri BP; Cance WG
    Mol Cancer Ther; 2013 Feb; 12(2):162-72. PubMed ID: 23243059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
    Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats TS
    Cancer Biol Ther; 2009 Oct; 8(20):1924-33. PubMed ID: 19738431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
    Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
    Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
    Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
    J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance.
    Chandra A; Jahangiri A; Chen W; Nguyen AT; Yagnik G; Pereira MP; Jain S; Garcia JH; Shah SS; Wadhwa H; Joshi RS; Weiss J; Wolf KJ; Lin JG; Müller S; Rick JW; Diaz AA; Gilbert LA; Kumar S; Aghi MK
    Cancer Res; 2020 Apr; 80(7):1498-1511. PubMed ID: 32041837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.